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624Objective: Chronic thromboembolic pulmonary hypertension is a rare form of pulmonary hypertension that can
lead to progressive right heart failure and death. Pulmonary thromboendarterectomy surgery is the treatment of
choice resulting in significant improvements in functional status, cardiopulmonary hemodynamics, and survival.
This study reports the largest case series of pediatric patients with chronic thromboembolic pulmonary hyperten-
sion who underwent pulmonary thromboendarterectomy surgery at one institution.
Patient and Methods: The University of California, San Diego, chronic thromboembolic pulmonary hyperten-
sion database identified patients 18 years or younger at the time of pulmonary thromboendarterectomy surgery
(n ¼ 17). Medical charts were reviewed for hemodynamics, thromboembolic risk factors, and postoperative
outcomes.
Results: Pulmonary thromboendarterectomy surgery in pediatric patients resulted in improved functional status
and significantly improved cardiopulmonary hemodynamics: mean arterial pressure decreased from 45.5 mm
Hg  20.7 to 27.3  13.0 mm Hg (P ¼ .00073), pulmonary vascular resistance decreased from 929  dynes
$ s $ cm5 to 299  307 dynes $ s $ cm5 (P ¼ .0012), and cardiac output improved from 3.8  1.1 L/min to
5.6 1.6 L/min (P¼ .0061). There were no deaths during surgery or 30 days after surgery, and long-term survival
(5þyears) was achieved in 87.5%. As compared to adults with chronic thromboembolic pulmonary hypertension,
there was a higher rate of rethrombosis in pediatric patients (38% vs 1%–4%).
Conclusions: This study demonstrates that pulmonary thromboendarterectomy surgery in pediatric patients with
chronic thromboembolic pulmonary hypertension is well tolerated with improved postoperative hemodynamics,
functional status, minimal postoperative complications, and low perioperative mortality, similar to that reported
for adults with chronic thromboembolic pulmonary hypertension, with the notable exception being a higher rate
of rethrombosis in pediatric patients. (J Thorac Cardiovasc Surg 2011;141:624-30)Chronic thromboembolic pulmonary hypertension (CTEPH)
is an uncommon, yet potentially curable form of pulmonary
hypertension.1 It occurs in 0.5% to 3.8% of patients after
acute or recurrent pulmonary embolus (PE) when there is
incomplete resolution of the thrombus burden.2,3
Transformation to a fibrotic residua results in chronic
proximal vessel obstruction. This, along with the
development of a distal arteriopathy similar to that seen in
idiopathic pulmonary arterial hypertension,4 can lead to pul-
monary hypertension and right ventricular overload. If left
untreated, right heart failure and death are the inevitable
end results.5 Pulmonary thromboendarterectomy (PTE) sur-
gery, however, offers an effective treatment for this condition,e Department of Cardiothoracic Surgerya and the Division of Pulmonary and
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gas exchange, functional status, and survival.6,7
As venous thromboembolism is increasingly recognized
in the pediatric patient population,8 CTEPH should be an
important diagnostic consideration in symptomatic children
with a known hypercoagulable state, a history of thrombo-
embolism or venous catheter placement, and/or a diagnosis
of pulmonary hypertension.9,10 This study presents a case
series of pediatric patients (>18 years of age) with CTEPH
who underwent PTE surgery at our institution. The
demographics, risk factors, surgical outcomes, and
postoperative complications in this unique subgroup of
CTEPH patients are reported.
PATIENTS AND METHODS
Retrospective review of the University of California San Diego’s (UCSD)
CTEPH database identified patients who were 18 years of age or younger at
the time of their PTE surgery. For the purposes of this study, informed consent
was waived and data collected in concordance with the standards set by our
institutional review board. All patients have been referred for consideration
of surgery, and nearly all underwent a standard preoperative evaluation
including chest radiograph, transthoracic echocardiography, ventilation–
perfusion scan, pulmonary angiography, right heart catheterization, and
hypercoagulable workup before or during their consultation at UCSD.ery c March 2011
Abbreviations and Acronyms
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
ICU ¼ intensive care unit
INR ¼ international normalized ratio
PE ¼ pulmonary embolus
PTE ¼ pulmonary thromboendarterectomy
PVR ¼ pulmonary vascular resistance
UCSD ¼ University of California San Diego
WHO ¼ World Health Organization
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ing a previously described standard technique.11 PTE involved a median
sternotomy, cardiopulmonary bypass, and deep hypothermia with periods
of circulatory arrest, followed by consecutive endarterectomy of the right
and left pulmonary arteries. This resulted in the removal of organized throm-
boembolic material from the vessel intima that was classified according to
the Jamieson scoring system as type 1 disease (semiorganized and chronic
thrombus in main or lobar pulmonary arteries), type 2 (fibrotic residua in lo-
bar or proximal segmental arteries without visible thrombus), type 3 (distal
segmental disease without visible thrombus), or type 4 (inoperable disease/
distal arteriolar vasculopathy).11 During the rewarming period, a persistent
foramen ovale (if present) was surgically closed so long as pulmonary
pressures had sufficiently normalized.
Patients’ immediate postoperative care took place in the intensive care
unit (ICU), where mechanical ventilation, inotropic support, and aggressive
diuresis were provided as long as necessary for recovery. For those patients
believed to be at a higher risk for rethrombosis after endarterectomy, such as
those with antiphospholipid syndrome or a main pulmonary artery endarter-
ectomy, intravenous heparin was started within 6 to 12 hours after the oper-
ation, once chest tube drainage had significantly abated. In those without
these risk factors, subcutaneous heparin was initiated. Postoperative throm-
bosis prophylaxis continued until the resumption of warfarin anticoagula-
tion resulted in a therapeutic international normalized ratio (INR).
Postoperative cardiopulmonary hemodynamics were measured by thermo-
dilution catheterization techniques before transfer out of the ICU with the
patients off both mechanical ventilation and inotropic agents. All other
postoperative studies, including transthoracic echocardiogram, ventila-
tion–perfusion scan, rest and exercise oxygen saturation testing, and chest
radiography occurred while the patients were convalescing on the general
hospital ward. Long-term follow-up (3 months to 7 years) was performed
by referring physicians, who communicated pertinent findings (echocardio-
grams, perfusion scans, and clinical updates) back to our institution.
Preoperative and postoperative hemodynamics were compared using an
exact 2-sided Wilcoxon rank sum test.
RESULTS
The first pediatric patient underwent PTE surgery at our
institution in 1998. Since then 16 other patients, 18 years
of age or younger, have successfully undergone PTE surgery
by our surgeons (n ¼ 17). This patient cohort constitutes
1.1% of the total number of operated CTEPH patients
(n ¼ 1498) at UCSD between 1998 and 2009.Demographics
Baseline patient data and clinical characteristics are
presented in Table 1. The age range of the patients in thisThe Journal of Thoracic and Caanalysis was 8 to18 years. There was a slight female predom-
inance (53%), and the majority were white (76%).
The most common presenting symptom was exertional
dyspnea and/or exercise intolerance (94%). Slightly less
than half had syncope or presyncope (47%). Other present-
ing symptoms included chest pain (35%), cough (29%), cy-
anosis (18%), edema (12%), and hemoptysis (12%). Only
35% of patients had known PE at the time of diagnosis,
and up to 42% had a history or ultrasound findings consis-
tent with a diagnosis of deep venous thrombosis. Idiopathic
pulmonary arterial hypertension was the initial diagnosis in
29%. A few patients were initially diagnosed with atypical
pneumonia (n¼ 3) or asthma (n¼ 2). Hypoxemia requiring
supplemental oxygen before surgery was present in 47% of
patients. As part of their management, 65% underwent infe-
rior vena caval filter placement before PTE surgery at
UCSD.
Thromboembolic Risk Factors
Fifteen (88%) of the 17 patients had 1 or more risk factors
for thromboembolism as depicted in Tables 1 and 2. Fifteen
of the 17 children had a hypercoagulable workup before PTE
surgery with 67% of them testing positive for an underlying
hypercoagulable state. The most common thrombophilic
states were lupus anticoagulant (n ¼ 5), anticardiolipin
antibody (n ¼ 4), and protein C deficiency (n ¼ 3), with 2
patients testing positive for both the lupus anticoagulant
and anticardiolipin antibody. One patient exhibited testing
suggestive of both protein C and S deficiency.
Antithrombin III, factor V Leiden, and prothrombin gene
defects were not seen in this cohort. A third of patients
(33%) had a positive family history of thromboembolism
and/or hypercoagulable state.
Other disorders seen in this cohort that are associated with
increased risk of thromboembolism12,13 include thoracic
inlet obstruction (n ¼ 2), the presence of a ventriculoatrial
shunt (n ¼ 1), nephrotic syndrome (n ¼ 1), and Klippel–
Trenaunay–Weber syndrome (n ¼ 1). Despite the young
age of this cohort, 3 of 9 female patients were either on
a regimen of contraceptive pills or were post partum at the
time of diagnosis. Only 1 patient had a history of
smoking. Another potential risk factor identified was
prolonged immobilization of a limb, with 3 (18%) patients
having a prior fracture of their upper or lower limbs.
However, the fracture did not appear to be related
(temporally or locally) to the subsequent development of
a deep venous thrombosis.
Severity of Illness
At presentation to UCSD, World Health Organization
(WHO) functional status was assessed as follows: class I,
2 (12%) of 17 patients; class II, 7 (41%) of 17 patients; class
III, 1 (6%) of 17 patients; and class IV, 7 (41%) of 17 pa-
tients. One of the patients in WHO class I status was deemedrdiovascular Surgery c Volume 141, Number 3 625
TABLE 1. Pediatric patient baseline demographics
Patient Age (y) Gender Race Thrombosis risk WHO score Initial diagnosis Oxygen IVC filter
1 16 F W PC 3 iPAH Y N
2 8 F W 4 iPAH Y N
3 16 M AA LA, ACLa 2 Lupus, DVT N Y
4 16 F W TIO 4 PE Y Y (SVC)
5 15 M AA Nephrotic syndrome 2 PE Y Y
6 13 F W ACLa, increased FVIII 4 PE N Y
7 17 M H PC, PS 2 iPAH N Y
8 11 M AA VA shunt 2 iPAH, VA thrombus N
9 16 M W LA, ACLa 1 Hilar mass, AVM N Y
10 17 F W PC 4 Asthma Y Y
11 13 F W LA 4 iPAH Y N
12 15 F W 1 PE N Y
13 17 M W TIO 2 Atypical PNA Y N
14 17 F W LA 2 ‘‘Saddle’’ PE N Y
15 10 M W KTW 4 Asthma Y Y
16 15 M W ACLa 4 PNA N Y
17 15 F W LA, borderline ACLa 2 PNA N N
WHO,World Health Organization; F, female;M, male;W, white; AA, African American; H, Hispanic; IVC, inferior vena cava; PC, protein C deficiency; LA, lupus anticoagulant;
ACLa, anticardiolipin antibody; TIO, thoracic inlet obstruction; FVIII, factor VIII; PS, protein S deficiency; VA shunt, ventriculoatrial shunt; KTW, Klippel–Trenaunay–Weber
syndrome; iPAH, idiopathic pulmonary arterial hypertension; DVT, deep venous thrombosis; PE, pulmonary embolus; VA, ventriculoatrial; AVM, arteriovenous malformation;
PNA, pneumonia; SVC, superior vena cava.
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main pulmonary artery chronic thromboembolic occlusive
disease. The operation was performed in an effort to prevent
the distal arteriopathy that can result from nonperfusion
of an entire lung.14 The other WHO class I patient had sig-
nificant collateral pulmonary circulation complicated byTABLE 2. Thromboembolic risk factors
Deep venous thrombosis
Known n ¼ 4
Suspected based on history 3
Thrombophilia
Lupus anticoagulant 5
Anticardiolipin antibody 4
Protein C deficiency 1
Protein S deficiency 1
Antithrombin III 0
Factor V Leiden 0
Prothrombin gene mutation 0
Elevated factor VIII 1
Smoking 1
Other risk factors
Thoracic inlet obstruction 2
Ventriculoatrial shunt 1
Nephrotic kidney disease 1
Klippel–Trenaunay–Weber 1
Splenectomy 0
Limb immobilization 3
Female patients only
Oral contraceptive pill use 2
Peripartum 1
Family history 5
626 The Journal of Thoracic and Cardiovascular Surghemoptysis. PTE surgery was performed to potentially re-
verse and/or mitigate further vascular collateralization.
Baseline pulmonary hemodynamic measurements are
shown in Table 3. For those patients with preoperative mea-
surements, mean pulmonary arterial pressure was 45.5 
20.7 mm Hg, mean cardiac output was 3.8  1.1 L/min,
and pulmonary vasculature resistance (PVR) was 929 
844 dynes $ s $ cm5. Preoperatively, 20% of our patients
had a PVR greater than 1000 dynes $s $ cm5, which has
been associated with increased perioperative mortality.15
At presentation to UCSD for PTE surgery, 18% were on
inotropic support: 1 patient was receiving milrinone and do-
butamine, 1 was receiving milrinone and dopamine, and 1
patient was receiving dobutamine alone. Forty-one percent
of patients were receiving pulmonary vasodilator therapy.
Preoperative pulmonary hypertension–specific pharmaco-
therapy included epoprostenol (n ¼ 3), treprostinil
(n ¼ 1), bosentan (n ¼ 3), sildenafil (n ¼ 4), and/or inhaled
nitric oxide (n ¼ 2).Surgical Results
Mean cardiopulmonary bypass time was 219 minutes,
mean right-sided circulatory arrest time 25 minutes, and
mean left-sided circulatory arrest time 22 minutes. Accord-
ing to the Jamieson scoring system, 40% had type 1 disease,
40% type 2, and 20% type 3. No one had type 4 disease. A
patent foramen ovale was closed in 4 patients (24%) and the
main pulmonary artery was enlarged with a pericardial patch
in 2 (12%) patients. Strikingly, 29% of patients had unilat-
eral main pulmonary artery disease, with the right main
pulmonary artery involved in 80% of these patients.ery c March 2011
TABLE 3. Cardiopulmonary hemodynamics before and after PTE surgery
Preoperative Postoperative
Patient Inotrope
PAH
Rx
PAP(m)
(mm Hg)
CO
(L/min)
PVR
(dynes $ s $ cm5) PAH Rx
PAP(m)
(mm Hg)
CO
(L/min)
PVR
(dynes $ s $ cm5)
1 63 4.21 969 32 8.5 188
2 E,B 93 2 3240 E 66 3.6 1311
3 40 4.1 624 27 8.3 125
4 M, Dopa E,B 56 1.87 2053 E,B 31
5 60 4.1 937 38 4.4 473
6 Dobut 14 5.64 85
7 31 4.51 337 19 7.15 101
8 S 900 370
9 39 4.55 563 24 5.59 157
10 50 4.83 563 25 4.6 304
11 iNO 57 2.2 1745 25 3.6 422
12 21 4.55 141 19 4.1 117
13 S,B 45 3 880 S,B 37 6.54 355
14 17 5.2 123 17 4.73 152
15 M, Dobut iNO,S,E,B S,B
16 S,T 48 4.1 741 16 6.7 131
17 17 4.27 112 20 5.4 193
Mean  SD 45.5  20.7 3.8  1.1 929  844 27.3  13.0* 5.6  1.6y 299  307z
PTE, Pulmonary thromboendarterectomy; PAH Rx, treatment for pulmonary arterial hypertension; PAP(m), pulmonary arterial pressure (mean); CO, cardiac output; PVR, pulmo-
nary vascular resistance. Inotropes: M, Milirinone; Dopa, dopamine; Dobut, dobutamine. PAH Rx: E, epoprostenol; B, bosentan; S, sildenafil; iNO, inhaled nitric oxide;
T, treprostinil. *P< .001. yP< .01. zP< .005.
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No pediatric patient in this series died in surgery or within
30 days after surgery at our institution. Long-term survival
(5þyears) was 87.5%. One pediatric death occurred in a pa-
tient with severe residual pulmonary hypertension (preoper-
ative PVR, 3720 dynes $ s $ cm5; postoperative PVR, 1311
dynes $ s $ cm5) and the other patient stopped long-term
anticoagulation and presented in pulseless electrical activity
arrest after recurrent massive PE.Outcomes After PTE Surgery
Median time to extubation was 1 day (range, 1–5 days),
median ICU stay 2 to 3 days (range, 2–11 days), and median
hospital days 9 to 10 days (7–16 days). Fourteen patients had
right heart catheterizations before and after PTE surgery; an-
other 2 had catheterization data from either before or after
surgery, but not both. There were dramatic improvements
in hemodynamics after surgery as detailed in Table 3:
mean pulmonary arterial pressure significantly decreased
from 45.5  20.7 mm Hg (range, 17–93 mm Hg) to
27.3  13.0 mm Hg (range, 16–66 mm Hg) (P ¼ .00073),
PVR decreased from 929  844 dynes $ s $ cm5
(range, 112–3420 dynes $ s $ cm5) to 299  307 dynes $
s $ cm5 (85–1311 dynes $ s $ cm5) (P¼ .0012) and cardiac
output improved from 3.8 1.1 L/min (range, 1.87–4.83 L/
min) to 5.6 1.6 L/min (range, 3.8–8.5 L/min) (P¼ .0061).
Only 1 patient had a PVR greater than 500 dynes $ s $ cm5
after surgery. None was discharged on inotropic or vasopres-
sor support, and 24% were discharged on pulmonary vaso-The Journal of Thoracic and Cadilators. Over half were free of cardiopulmonary symptoms
(WHO class I) at follow-up, which ranges from 3 months to
7 years in this cohort.
There was, however, a significantly high rate of rethrom-
bosis, occurring in up to 38% of patients having undergone
PTE surgery (n¼ 6). This development occurred despite the
fact that 59% of these patients were discharged with instruc-
tions to maintain an INR goal of 3 or more. Of those that had
recurrent PE, 2 patients were known to have stopped their
anticoagulation before rethrombosis, and 2 patients went
on to require repeat PTE surgery.Postoperative Complications
PTE surgery was generally well tolerated by all patients.
Table 4 lists common postoperative complications and their
occurrence in this population. Although reperfusion lung in-
jury can occur in up to 40% of adult CTEPH patients,16,17
only 1 patient in this series had mild reperfusion lung
injury requiring 2 extra days of supportive care in the
ICU. No bleeding complications were noted in our
patients despite the relatively aggressive postoperative
anticoagulation and higher (3) INR goals in the majority
of patients. However, 5 (29%) patients had moderate–
severe pericardial effusions with 3 patients having
tamponade physiology. The onset of these effusions,
except one, occurred 2 to 3 weeks after discharge from the
hospital. In 1 patient the effusion resolved with diuresis
alone, 3 required steroids, 2 underwent pericardiocentesis,
and 1 patient required a pericardial window. A relativelyrdiovascular Surgery c Volume 141, Number 3 627
TABLE 4. Complications after PTE surgery
Rethrombosis 6 (38%)*
Hemorrhage requiring surgical exploration 0y
Pneumothorax 2
Phrenic nerve injury 0
Recurrent laryngeal nerve injury 1
Wound infection 0
Moderate–severe pericardial effusion 5 (29%)*
Pericardial effusion with tamponade physiology 3
Pneumonia 0
Reperfusion lung injury 1y
Atrial arrhythmias 0
Residual pulmonary hypertension
(PVR>500 dynes $ s $ cm5)
1y
On PAH pharmacotherapy at discharge 4 (24%)
Delirium 2 (12%)*
Transient choreiform movements 1
PTE, Pulmonary thromboendarterectomy; PVR, pulmonary vascular resistance; PAH,
pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hyper-
tension. *Complications seen in higher frequency in pediatric CTEPH patients than
CTEPH patients in general. yComplications seen in lower frequency in pediatric
CTEPH patients than CTEPH patients in general.
Congenital Heart Disease Madani et alC
H
Dhigh incidence of postoperative delirium developed at a rate
of 12% in this pediatric group, believed to be secondary to
narcotic sensitivity in this opiod-naı¨ve cohort.DISCUSSION
This report details the largest case series of pediatric
CTEPH patients who have successfully undergone PTE
surgery, emphasizing not only that this operation is well
tolerated, but also that it is associated with low morbidity,
low mortality, and significant improvement in pulmonary
hemodynamics and right heart function. This study also
serves to highlight important features of pediatric CTEPH
patients, including the increased presence of thrombophilic
disorders, main pulmonary artery disease, and recurrent
thrombosis risk.
Overall, the pediatric patient group makes up a small per-
centage (1.1%) of the CTEPH patients who have undergone
PTE surgery at our institution. CTEPH is generally under-
recognized in the population at large,1 and this may be sim-
ilarly true for pediatric patients. As is the case for adults,
over half of the patients in this series did not have signs
and symptoms indicative of acute embolism or deep venous
thrombosis. Therefore, it is important for care providers
to have a high index of suspicion for the possibility of
pulmonary vascular disease in children who have exercise
intolerance or exertional dyspnea. This is particularly true
when a congenital heart condition has been ruled out and
when the clinical picture does not support an alternative di-
agnosis such as asthma. There should be even more concern
for the diagnosis if presyncope or syncope is present.
Screening these children for CTEPH with ventilation–perfu-
sion scanning is imperative inasmuch as a normal scan will628 The Journal of Thoracic and Cardiovascular Surgcompletely rule out CTEPH. However, in patients with ab-
normal scans indicative of CTEPH, PTE surgery is largely
curable and the natural history of this disease without
surgery is extremely poor.5
In this study, 67% of the pediatric patients who had
chronic thromboembolic disease exhibited an underlying
thrombophilic disorder. This is in contrast to the adult
CTEPH population, in which only 20% to 40% are reported
to have a contributing hypercoagulable state.1,18,19 Lupus
anticoagulant, anticardiolipin antibodies, and protein C
deficiency were the most common predisposing
thrombophilic states in this pediatric cohort. Even though
antithrombin III, factor V Leiden, or prothrombin gene
mutations were not detected, it does not exclude the
possibility that children with these underlying disorders
may also be at increased risk for CTEPH. In those without
a hypercoagulable disorder, a different thromboembolic
risk factor (ie, ventriculoarterial shunt, Klippel–
Trenaunay–Weber syndrome) was often present.
Therefore, in children who have PE with an underlying
hypercoagulable state and/or other thromboembolic risk
factor, careful follow-up would be recommended to ensure
complete resolution of the thrombus burden.
For selected patients with CTEPH, PTE surgery is the
preferred treatment option given its established efficacy in
improving cardiopulmonary hemodynamics, functional sta-
tus, oxygenation, and survivorship.6,7,15-17,20-22 At baseline,
most of the children were ill (WHO classes 2–4) and
exhibited preoperative disease severity similar to adult
CTEPH patients who have undergone PTE surgery.16,17,20-22
Over 40% of pediatric patients referred to UCSD were
already receiving pharmacologic pulmonary arterial
hypertension therapy, a rate similar to that currently
seen in adult patients with operable CTEPH referred to
UCSD for surgical consideration.23 This may reflect de-
layed recognition of CTEPH, a hesitancy to refer children
for PTE surgery, an attempt to clinically stabilize those
children with markedly elevated PVRs and right heart
dysfunction, or simply reflect a growing trend to use
medical therapies owing to the increased availability of
pulmonary hypertension–specific medications.24
This study confirms that pediatric patients benefit dramat-
ically from surgery and tolerate the operation well with
significantly improved cardiopulmonary hemodynamics
after PTE surgery. No deaths occurred in hospital or within
30 days of discharge at our institution. Long-term survival
after PTE was 87.5%, which is comparable with that of
the CTEPH population at large (75%–88.7% survival).6,7
The majority of patients were asymptomatic at follow-up.
Therefore, at medical centers experienced with PTE surgery
and equipped to accommodate children, pediatric patients
can have excellent outcomes from surgery. Because CTEPH
is believed to lead to a progressive distal arteriopathy that is
not responsive to surgery,4 prompt referral for PTE surgeryery c March 2011
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should not be seen as an impediment to surgery.
Given the relatively small number of patients in this re-
ported series, it is difficult to conclude that there are signif-
icant differences in postoperative complications when
compared with the adult CTEPH patient. However, certain
trends were observed. Reperfusion lung injury has been re-
ported as a complication of PTE surgery (16%–36% of sur-
gically treated patients) and is a leading cause of mortality
from this surgical procedure.16,17 In this series, only 1
patient had mild reperfusion lung injury that responded
quickly (within 48 hours) to supportive measures. In
addition, significant postoperative bleeding difficulties
were rare. This was remarkable inasmuch as aggressive
anticoagulation regimens were administered to almost
60% of the patients. Conversely, seen more frequently
relative to older patients were pericardial fluid collections
that required intervention. Five (29%) of the pediatric
patients had moderate to severe pericardial effusions after
PTE, which is double the frequency (3%–15%) seen in
adult CTEPH patients.16,17 Of these, 3 had cardiac
tamponade and 4 of these episodes occurred 2 to 3 weeks
after discharge from the hospital. It is not entirely clear
why these patients might be at increased risk of having
late, large pericardial effusions, although 3 of the 5
affected also had antiphospholipid antibodies. Whether an
immune mechanism is important in the etiology of these
effusions requires further investigation. What is evident,
however, is that careful assessment is required for those
pediatric patients who have an unexpected pain pattern,
particularly in the chest, back, or shoulder region, several
weeks after PTE surgery.
Despite the successful PTE operations in this cohort, there
were 2 deaths that occurred during follow-up. One was from
the sequelae of residual pulmonary hypertension and the
other from rethrombosis when anticoagulation was stopped
prematurely. Over a third of the patients (38%) in this series
went on to have new pulmonary thromboemboli as com-
pared with only 1% to 4% of adult CTEPH patients.1,25
Factors potentially contributing to the development of
postoperative thrombosis include the high rate of
a thrombophilic state in the pediatric patient group, along
with a higher incidence of unilateral, main pulmonary
arterial disease (29% vs 3% of adult CTEPH patients).
The latter has been associated with a much higher risk of
rethrombosis.14 This report also demonstrated that some of
the pediatric patients who had repeat PE discontinued
anticoagulation prematurely. This emphasizes the need for
extensive, even repetitive, counseling of children with
CTEPH regarding the importance of lifelong anticoagula-
tion. It is not clear whether the use of inferior vena cava
filters would benefit this population or decrease the risk of
recurrent thrombosis, so no particular recommendation can
be made in this regard. However, it is the practice at our in-The Journal of Thoracic and Castitution to aggressively anticoagulate any patient with main
pulmonary artery disease or those with antiphospholipid an-
tibodies with a continuous intravenous heparin infusion in
the immediate postoperative period and to target higher
INR goals (3.0–3.5 or 3.0–4.0) once there has been a transi-
tion to warfarin. In the setting of recurrent, surgical CTEPH,
a second PTE may be feasible, as was the case for 2 patients
in this series, and should be considered if clinically
indicated.CONCLUSIONS
This study demonstrates that pediatric CTEPH is rare,
but amenable to PTE surgery, with excellent hemodynamic
and survival outcomes. Patients should be carefully
screened for underlying hypercoagulable states, and in
those patients at highest risk for rethrombosis (ie, unilateral
disease and positive anticardiolipin antibody), consider-
ation should be given to placing an inferior vena cava filter
and maintaining higher INR goals to reduce the likelihood
of disease recurrence. All pediatric CTEPH patients deserve
extensive counseling about the need for strict, lifelong ad-
herence to anticoagulation. Inasmuch as there has been
a dramatic increase in the recognition of venous thrombo-
embolism in children over the past decade, special attention
needs to be given to those whose emboli do not resolve.
Referral for evaluation and possible PTE surgery should
happen promptly to medical centers experienced and equip-
ped to perform this surgery in children to minimize the dis-
tal vasculopathy that appears to occur over time in this
disease.
We appreciate the collaboration with our biostatistician Aaron
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